Price to FCFE (P/FCFE)
Free Cash Flow to Equity (FCFE)
Moderna Inc., FCFE calculation
US$ in millions
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Item | Description | The company |
|---|---|---|
| FCFE | Free cash flow to equity is the cash flow available to Moderna Inc. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. | Moderna Inc. FCFE decreased from 2021 to 2022 and from 2022 to 2023. |
Price to FCFE Ratio, Current
Moderna Inc., current P/FCFE calculation, comparison to benchmarks
| No. shares of common stock outstanding | 384,817,811 |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in millions) | (4,095) |
| FCFE per share | -10.64 |
| Current share price (P) | 50.28 |
| Valuation Ratio | |
| P/FCFE | — |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| AbbVie Inc. | 16.96 |
| Amgen Inc. | 4.43 |
| Bristol-Myers Squibb Co. | 8.71 |
| Danaher Corp. | 49.29 |
| Eli Lilly & Co. | 72.96 |
| Gilead Sciences Inc. | 16.01 |
| Johnson & Johnson | 22.82 |
| Merck & Co. Inc. | 18.59 |
| Pfizer Inc. | 3.66 |
| Regeneron Pharmaceuticals Inc. | 19.33 |
| Thermo Fisher Scientific Inc. | 31.21 |
| Vertex Pharmaceuticals Inc. | 33.01 |
| P/FCFE, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 16.03 |
| P/FCFE, Industry | |
| Health Care | 16.26 |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Moderna Inc., historical P/FCFE calculation, comparison to benchmarks
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 382,073,208 | 386,339,594 | 402,872,986 | 399,769,582 | 368,642,548 | |
| Selected Financial Data (US$) | ||||||
| Free cash flow to equity (FCFE) (in millions)2 | (4,095) | 4,397) | 13,196) | 1,953) | (490) | |
| FCFE per share3 | -10.72 | 11.38 | 32.75 | 4.89 | -1.33 | |
| Share price1, 4 | 96.46 | 139.26 | 151.33 | 154.81 | 26.16 | |
| Valuation Ratio | ||||||
| P/FCFE5 | — | 12.24 | 4.62 | 31.68 | — | |
| Benchmarks | ||||||
| P/FCFE, Competitors6 | ||||||
| AbbVie Inc. | 17.37 | 22.66 | 18.76 | 13.16 | 3.64 | |
| Amgen Inc. | 4.71 | 8.32 | 13.52 | 11.06 | 33.32 | |
| Bristol-Myers Squibb Co. | 7.52 | 22.85 | 16.17 | 7.80 | 5.80 | |
| Danaher Corp. | 53.08 | 32.04 | 20.75 | 44.62 | 6.88 | |
| Eli Lilly & Co. | 75.06 | 60.51 | 35.17 | 36.62 | 15.87 | |
| Gilead Sciences Inc. | 12.81 | 15.22 | 12.70 | 5.98 | 15.91 | |
| Johnson & Johnson | 24.31 | 16.73 | 23.28 | 15.60 | 23.06 | |
| Merck & Co. Inc. | 24.48 | 22.40 | 18.72 | 17.85 | 18.08 | |
| Pfizer Inc. | 3.82 | 10.56 | 8.88 | — | 9.87 | |
| Regeneron Pharmaceuticals Inc. | 26.52 | 19.29 | 10.35 | 13.30 | 21.00 | |
| Thermo Fisher Scientific Inc. | 31.16 | 27.98 | 13.44 | 18.58 | 46.04 | |
| Vertex Pharmaceuticals Inc. | 33.45 | 19.91 | 26.08 | 18.46 | 42.50 | |
| P/FCFE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 16.91 | 19.28 | 16.49 | 17.09 | 11.66 | |
| P/FCFE, Industry | ||||||
| Health Care | 16.85 | 18.12 | 17.81 | 17.23 | 13.56 | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
3 2023 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= -4,095,000,000 ÷ 382,073,208 = -10.72
4 Closing price as at the filing date of Moderna Inc. Annual Report.
5 2023 Calculation
P/FCFE = Share price ÷ FCFE per share
= 96.46 ÷ -10.72 = —
6 Click competitor name to see calculations.